Fig. 1

A: Comparison of VCM AUC between AKI group and no-AKI group; median (range): 561 (543‒712) mg·h/L and 380 (185‒600) mg·h/L, respectively. Solid bars denote median values. Open circles show patients who developed clinical failure. Open triangle shows one patient whose record regarding the outcome of infectious disease was not available due to transfer to another institute. B: Comparison of VCM trough levels between AKI group and no-AKI group; median (range): 13.3 (9.1‒15.5) µg/mL vs. 10.6 (2.2‒17.0) µg/mL, respectively. Open circles show patients who developed clinical failure. Open triangle shows one patient whose record regarding the outcome of infectious disease was not available due to transfer to another institute. C: Comparison of GM trough levels between AKI group and no-AKI group; median (interquartile range): 0.7 (0.4‒1.3) µg/mL and 0.6 (0.1‒1.8) µg/mL, respectively. Solid bars denote median values. Closed squares show patients treated with once daily administration of GM. Open squares show patients treated with twice or three times daily administration of GM. D: Comparison of concomitant duration of vancomycin and gentamicin between AKI group and no-AKI group; median (range): 12 (7‒22) days and 8 (4‒25) days, respectively. Solid bars denote median values. Abbreviations: AKI; acute kidney injury, AUC; area under the curve, GM; gentamicin, mono; monotherapy, VCM; vancomycin